Performance characteristics of a modified HIV-1 drug resistance genotyping method for use in resource-limited settings [version 1; peer review: 2 approved]
Background: HIV-1 drug resistance (HIVDR) assays are critical components of HIV clinical management programs in the face of emerging drug resistance. However, the high costs associated with existing commercial HIVDR assays prohibit their routine usage in resource-limited settings. We present the per...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2019-08-01
|
Series: | F1000Research |
Online Access: | https://f1000research.com/articles/8-1518/v1 |
id |
doaj-49b049579d9f458cb32f9ff1cedf1846 |
---|---|
record_format |
Article |
spelling |
doaj-49b049579d9f458cb32f9ff1cedf18462020-11-25T02:32:05ZengF1000 Research LtdF1000Research2046-14022019-08-01810.12688/f1000research.20083.122050Performance characteristics of a modified HIV-1 drug resistance genotyping method for use in resource-limited settings [version 1; peer review: 2 approved]Edwin O. Magomere0Donald D. Nyangahu1Sammy Kimoloi2Brenda A. Webala3Bartholomew N. Ondigo4Department of Biochemistry and Molecular Biology, Egerton University, Nakuru, Nakuru, 20115, KenyaCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USADepartment of Medical Laboratory Sciences, Masinde Muliro University of Science and Technology, Kakamega, Kakamega, KenyaFaculty of Health Sciences, Egerton University, Nakuru, Nakuru, KenyaDepartment of Biochemistry and Molecular Biology, Egerton University, Nakuru, Nakuru, 20115, KenyaBackground: HIV-1 drug resistance (HIVDR) assays are critical components of HIV clinical management programs in the face of emerging drug resistance. However, the high costs associated with existing commercial HIVDR assays prohibit their routine usage in resource-limited settings. We present the performance characteristics of a modified commercial HIVDR testing assay. Methods: A total of 26 plasma samples were used to validate and assess the accuracy, precision, reproducibility and amplification sensitivity of a modified HIVDR assay by HIV genotyping. In addition, a cost comparison between the original and the modified assay was performed using the ingredient costing approach. Results: The performance characteristics of the modified assay were in agreement with the original assay. Accuracy, precision and reproducibility showed nucleotide sequence identity of 98.5% (confidence interval (CI), 97.9–99.1%), 98.67% (CI, 98.1–99.23) and 98.7% (CI, 98.1–99.3), respectively. There was no difference in the type of mutations detected by the two assays (χ2 = 2.36, p = 0.26). Precision and reproducibility showed significant mutation agreement between replicates (kappa = 0.79 and 0.78), respectively (p < 0.05). The amplification sensitivity of the modified assay was 100% and 62.5% for viremia ≥1000 copies/ml and <1000 copies/ml respectively. Our assay modification translates to a 39.2% reduction in the cost of reagents. Conclusions: Our findings underscore the potential of modifying commercially available HIVDR testing assays into cost-effective, yet accurate assays for use in resource-limited settings.https://f1000research.com/articles/8-1518/v1 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Edwin O. Magomere Donald D. Nyangahu Sammy Kimoloi Brenda A. Webala Bartholomew N. Ondigo |
spellingShingle |
Edwin O. Magomere Donald D. Nyangahu Sammy Kimoloi Brenda A. Webala Bartholomew N. Ondigo Performance characteristics of a modified HIV-1 drug resistance genotyping method for use in resource-limited settings [version 1; peer review: 2 approved] F1000Research |
author_facet |
Edwin O. Magomere Donald D. Nyangahu Sammy Kimoloi Brenda A. Webala Bartholomew N. Ondigo |
author_sort |
Edwin O. Magomere |
title |
Performance characteristics of a modified HIV-1 drug resistance genotyping method for use in resource-limited settings [version 1; peer review: 2 approved] |
title_short |
Performance characteristics of a modified HIV-1 drug resistance genotyping method for use in resource-limited settings [version 1; peer review: 2 approved] |
title_full |
Performance characteristics of a modified HIV-1 drug resistance genotyping method for use in resource-limited settings [version 1; peer review: 2 approved] |
title_fullStr |
Performance characteristics of a modified HIV-1 drug resistance genotyping method for use in resource-limited settings [version 1; peer review: 2 approved] |
title_full_unstemmed |
Performance characteristics of a modified HIV-1 drug resistance genotyping method for use in resource-limited settings [version 1; peer review: 2 approved] |
title_sort |
performance characteristics of a modified hiv-1 drug resistance genotyping method for use in resource-limited settings [version 1; peer review: 2 approved] |
publisher |
F1000 Research Ltd |
series |
F1000Research |
issn |
2046-1402 |
publishDate |
2019-08-01 |
description |
Background: HIV-1 drug resistance (HIVDR) assays are critical components of HIV clinical management programs in the face of emerging drug resistance. However, the high costs associated with existing commercial HIVDR assays prohibit their routine usage in resource-limited settings. We present the performance characteristics of a modified commercial HIVDR testing assay. Methods: A total of 26 plasma samples were used to validate and assess the accuracy, precision, reproducibility and amplification sensitivity of a modified HIVDR assay by HIV genotyping. In addition, a cost comparison between the original and the modified assay was performed using the ingredient costing approach. Results: The performance characteristics of the modified assay were in agreement with the original assay. Accuracy, precision and reproducibility showed nucleotide sequence identity of 98.5% (confidence interval (CI), 97.9–99.1%), 98.67% (CI, 98.1–99.23) and 98.7% (CI, 98.1–99.3), respectively. There was no difference in the type of mutations detected by the two assays (χ2 = 2.36, p = 0.26). Precision and reproducibility showed significant mutation agreement between replicates (kappa = 0.79 and 0.78), respectively (p < 0.05). The amplification sensitivity of the modified assay was 100% and 62.5% for viremia ≥1000 copies/ml and <1000 copies/ml respectively. Our assay modification translates to a 39.2% reduction in the cost of reagents. Conclusions: Our findings underscore the potential of modifying commercially available HIVDR testing assays into cost-effective, yet accurate assays for use in resource-limited settings. |
url |
https://f1000research.com/articles/8-1518/v1 |
work_keys_str_mv |
AT edwinomagomere performancecharacteristicsofamodifiedhiv1drugresistancegenotypingmethodforuseinresourcelimitedsettingsversion1peerreview2approved AT donalddnyangahu performancecharacteristicsofamodifiedhiv1drugresistancegenotypingmethodforuseinresourcelimitedsettingsversion1peerreview2approved AT sammykimoloi performancecharacteristicsofamodifiedhiv1drugresistancegenotypingmethodforuseinresourcelimitedsettingsversion1peerreview2approved AT brendaawebala performancecharacteristicsofamodifiedhiv1drugresistancegenotypingmethodforuseinresourcelimitedsettingsversion1peerreview2approved AT bartholomewnondigo performancecharacteristicsofamodifiedhiv1drugresistancegenotypingmethodforuseinresourcelimitedsettingsversion1peerreview2approved |
_version_ |
1724821562860765184 |